SubHero Banner

Jemperli® (dostarlimab-gxly) – New indication

July 31, 2023 - The FDA announced the approval of GSK’s Jemperli (dostarlimab-gxly), in combination with carboplatin and paclitaxel, followed by Jemperli as a single agent for the treatment of adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR), as determined by an FDA-approved test, or microsatellite instability-high (MSI-H).

Download PDF